[MASLD的诊断和治疗管理]
1Med. Klinik m. S. Hepatologie und Gastroenterologie, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum und Campus Charité Mitte, Augustenburger Pl. 1, 13353, Berlin, Deutschland.
Innere Medizin (Heidelberg, Germany)
|May 26, 2025
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 影响全球25-35%,与胰岛素抵抗和肥胖有关. 目前的治疗方法主要集中在减肥上,新药治疗脂肪肝炎即将获得批准.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢疾病 代谢疾病
- 心脏病学 心脏病学
背景情况:
- 代谢功能障碍相关的脂肪性肝病 (MASLD),以前是脂肪性肝病,在全球普遍存在 (25-35%).
- MASLD与胰岛素抵抗,肥胖和心脏代谢风险因素密切相关.
- 它是肝硬化,肝细胞癌和心血管事件风险增加的主要原因.
研究的目的:
- 审查目前对MASLD诊断和管理的理解.
- 突出MASLD日益增长的流行和社会经济影响.
- 讨论MASLD和相关的脂肪肝炎的新兴治疗策略.
主要方法:
- 审查目前的MASLD诊断标准,强调非侵入性手术.
- 分析治疗方法,包括改变生活方式和药理干预措施.
- 检查GLP-1激动剂和减肥手术在MASLD管理中的作用.
主要成果:
- 诊断MASLD依赖于成像和心脏代谢风险标准.
- 非侵入性方法越来越多地优先于肝活检用于纤维化评估.
- 生活方式干预,GLP-1激动剂和减肥手术在治疗MASLD方面显示出有前途.
结论:
- MASLD是一个重要的全球健康问题,需要有效的管理策略.
- 非侵入性诊断和生活方式的改变是当前MASLD护理的关键组成部分.
- 对于脂肪肝炎的新兴药物疗法提供了未来的治疗可能性.
相关概念视频
Mitral Stenosis III: Medical Management
31
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
31
Cardiomyopathy V: Interprofessional Care
42
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
42
Myocarditis III: Medical Management
22
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
22
Mitral Stenosis IV: Nursing Management
54
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
54
Mitral Valve Prolapse II: Assessment and Management
49
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
49
Mitral Regurgitation III: Medical Management
36
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
36


